425 related articles for article (PubMed ID: 31322018)
1. Overall and comparative safety of biologic and immunosuppressive therapy in inflammatory bowel diseases.
Holmer A; Singh S
Expert Rev Clin Immunol; 2019 Sep; 15(9):969-979. PubMed ID: 31322018
[No Abstract] [Full Text] [Related]
2. Management of inflammatory bowel disease with infliximab and other anti-tumor necrosis factor alpha therapies.
Magro F; Portela F
BioDrugs; 2010 Dec; 24 Suppl 1():3-14. PubMed ID: 21175228
[TBL] [Abstract][Full Text] [Related]
3. Comparative Risk of Serious Infections With Biologic and/or Immunosuppressive Therapy in Patients With Inflammatory Bowel Diseases: A Systematic Review and Meta-Analysis.
Singh S; Facciorusso A; Dulai PS; Jairath V; Sandborn WJ
Clin Gastroenterol Hepatol; 2020 Jan; 18(1):69-81.e3. PubMed ID: 30876964
[TBL] [Abstract][Full Text] [Related]
4. Crohn's targeted therapy: myth or real goal?
Schmidt KJ; Büning J; Jankowiak C; Lehnert H; Fellermann K
Curr Drug Discov Technol; 2009 Dec; 6(4):290-8. PubMed ID: 20025597
[TBL] [Abstract][Full Text] [Related]
5. The use of biologic agents in pregnancy and breastfeeding.
Horst S; Kane S
Gastroenterol Clin North Am; 2014 Sep; 43(3):495-508. PubMed ID: 25110255
[TBL] [Abstract][Full Text] [Related]
6. Tumor necrosis factor-alpha antibody for maintenance of remission in Crohn's disease.
Behm BW; Bickston SJ
Cochrane Database Syst Rev; 2008 Jan; (1):CD006893. PubMed ID: 18254120
[TBL] [Abstract][Full Text] [Related]
7. Biologic-Induced Infections in Inflammatory Bowel Disease: The TNF-α Antagonists.
McConachie SM; Wilhelm SM; Bhargava A; Kale-Pradhan PB
Ann Pharmacother; 2018 Jun; 52(6):571-579. PubMed ID: 29363355
[TBL] [Abstract][Full Text] [Related]
8. Comparative Effectiveness and Safety of Anti-Tumor Necrosis Factor Agents in Biologic-Naive Patients With Crohn's Disease.
Singh S; Heien HC; Sangaralingham LR; Schilz SR; Kappelman MD; Shah ND; Loftus EV
Clin Gastroenterol Hepatol; 2016 Aug; 14(8):1120-1129.e6. PubMed ID: 27058635
[TBL] [Abstract][Full Text] [Related]
9. The association of psoriasiform rash with anti-tumor necrosis factor (anti-TNF) therapy in inflammatory bowel disease: a single academic center case series.
Afzali A; Wheat CL; Hu JK; Olerud JE; Lee SD
J Crohns Colitis; 2014 Jun; 8(6):480-8. PubMed ID: 24268978
[TBL] [Abstract][Full Text] [Related]
10. Optimizing anti-TNF treatment in inflammatory bowel disease.
Rutgeerts P; Van Assche G; Vermeire S
Gastroenterology; 2004 May; 126(6):1593-610. PubMed ID: 15168370
[TBL] [Abstract][Full Text] [Related]
11. [Pharmacology of biologic medications].
Marusić M; Mihaljević S
Acta Med Croatica; 2013 Apr; 67(2):125-30. PubMed ID: 24471295
[TBL] [Abstract][Full Text] [Related]
12. Comparative effectiveness of immunosuppressants and biologics for inducing and maintaining remission in Crohn's disease: a network meta-analysis.
Hazlewood GS; Rezaie A; Borman M; Panaccione R; Ghosh S; Seow CH; Kuenzig E; Tomlinson G; Siegel CA; Melmed GY; Kaplan GG
Gastroenterology; 2015 Feb; 148(2):344-54.e5; quiz e14-5. PubMed ID: 25448924
[TBL] [Abstract][Full Text] [Related]
13. Systematic review with meta-analysis: the efficacy of a second anti-TNF in patients with inflammatory bowel disease whose previous anti-TNF treatment has failed.
Gisbert JP; Marín AC; McNicholl AG; Chaparro M
Aliment Pharmacol Ther; 2015 Apr; 41(7):613-23. PubMed ID: 25652884
[TBL] [Abstract][Full Text] [Related]
14. Tumor necrosis factor blockade for treatment of inflammatory bowel disease: efficacy and safety.
Ngo B; Farrell CP; Barr M; Wolov K; Bailey R; Mullin JM; Thornton JJ
Curr Mol Pharmacol; 2010 Nov; 3(3):145-52. PubMed ID: 20799925
[TBL] [Abstract][Full Text] [Related]
15. State-of-the-art: Immunosuppression and biologic therapy.
Sandborn WJ
Dig Dis; 2010; 28(3):536-42. PubMed ID: 20926883
[TBL] [Abstract][Full Text] [Related]
16. [TNF-alpha blocking therapy in chronic inflammatory bowel disease].
Molnár T
Orv Hetil; 2009 Sep; 150(38):1773-9. PubMed ID: 19740722
[TBL] [Abstract][Full Text] [Related]
17. Is there a benefit from the concomitant use of immunosupression with anti-TNF in Crohn's disease; heads or tails?
Lakatos PL
Rev Recent Clin Trials; 2009 Sep; 4(3):152-8. PubMed ID: 20028325
[TBL] [Abstract][Full Text] [Related]
18. Certolizumab pegol: new drug. As a last resort in Crohn's disease: continue to use other TNF alpha inhibitors.
Prescrire Int; 2009 Jun; 18(101):108-10. PubMed ID: 19637418
[TBL] [Abstract][Full Text] [Related]
19. Experience With Anti-TNF-α Biologic Agents in Succession in Patients With Crohn's Disease: A Retrospective Analysis of a Single Center.
Ferges W; Rampertab SD; Shafqet M; Salimi Q; You G; Yousefzadeh E; Cheng JQ; Das KM
J Clin Gastroenterol; 2016 Apr; 50(4):326-30. PubMed ID: 25984976
[TBL] [Abstract][Full Text] [Related]
20. [Place of biologic therapy in the treatment of inflammatory bowel diseases and assessment of its efficacy].
Krznarić Z; Stimac D; Franjić N; Kunović A; Kelecić DL
Acta Med Croatica; 2013 Apr; 67(2):145-55. PubMed ID: 24471297
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]